Rani Therapeutics Holdings, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Rani is a clinical-stage biotherapeutics company developing oral drug-delivery technology. It has no products approved for sale and generated no commercial product revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | No commercial product revenue | No commercial product revenue |
| Research and development expense | $7.6 million | $9.7 million |
| General and administrative expense | $6.4 million | $6.8 million |
| Total operating expenses | $14.0 million | $16.5 million |
| Net loss | $14.8 million | $16.8 million |
| Net loss attributable to Rani Holdings | $7.5 million; $0.29 per share | $8.4 million; $0.33 per share |
| Net cash used in operating activities | $9.4 million | $12.2 million |
Margins are not meaningful because the company reported no commercial revenue. R&D expense fell 21.9%, primarily due to lower compensation costs following workforce reductions and lower third-party service costs. G&A expense declined 5.2%. Interest income decreased and interest expense increased, partly offsetting the lower operating loss.
At March 31, cash and cash equivalents were $6.9 million and marketable securities were $32.7 million, totaling $39.6 million, down from $48.5 million at December 31, 2023. Total assets were $53.5 million; total liabilities were $39.0 million. Debt principal was $30.0 million, with a $29.4 million carrying value after debt discount. The loan’s effective interest rate was 15.66%; principal repayments are scheduled to begin in September 2024, with possible extension to March 2025 under certain conditions. The company reported covenant compliance and no loan defaults.
Material changes and business developments
- Cash from operations used improved year over year, while the net loss narrowed by 12.2%.
- In February 2024, Rani announced positive topline Phase 1 results for RT-111, an oral ustekinumab biosimilar candidate: the study met its endpoints, was generally well tolerated, and reported no serious adverse events. The filing reports high bioavailability for the tested doses and no meaningful difference in anti-drug antibody incidence versus subcutaneous STELARA.
- Rani has completed three Phase 1 trials using the RaniPill GO. It plans to initiate clinical testing of the higher-capacity RaniPill HC in the second half of 2024; this remains a forward-looking plan.
- Q1 investing cash inflow of $10.3 million primarily reflected maturities of marketable securities exceeding purchases; financing cash inflow was $0.1 million.
Outlook, risks, and unusual items
- Going concern: Management concluded substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance of the Q1 financial statements. Current resources are not sufficient to fund projected requirements for 12 months or to initiate pivotal trials. Additional financing will be needed, and management’s plans do not alleviate the substantial doubt.
- Rani expects continuing operating losses and negative operating cash flows and says it needs substantial additional funding for development, clinical trials, manufacturing expansion, and commercialization. Potential funding sources include equity, debt, and collaborations, but availability and terms are uncertain. Its $150 million at-the-market sales agreement had no sales through March 31, 2024. An additional $15 million loan facility is uncommitted, conditional, and subject to lender approval.
- A November 2023 restructuring reduced the workforce by approximately 25%. The company estimates about $0.3 million in restructuring costs, nearly all cash, and expects completion by the end of Q2 2024. The CEO’s annual salary was reduced from $520,000 to $100,000 through December 31, 2024, or until specified financing or transaction proceeds are received.
- A new Fremont lease commenced in February 2024 for approximately 33,000 square feet, with a 63-month initial term and base rent of about $95,000 monthly, increasing 4% annually, plus additional operating costs.
- The company is involved in European Patent Office opposition proceedings asserted by Novo Nordisk. Management says a loss is not probable or reasonably estimable; the outcome could affect its ability to prevent similar products from being commercialized in Europe.
- A potential Tax Receivable Agreement liability is unrecorded because realization of the related tax benefits is not considered probable. Potential payments range from zero to $23.1 million, depending on future circumstances.
- Facilities and certain services are provided through related-party agreements with InCube Labs, an entity affiliated with the founder and Chairman. Related-party charges were $0.4 million in Q1 2024.
Key facts investors should verify
- Cash burn, remaining liquidity, and the timing, amount, and terms of any required financing.
- Progress and timing of RaniPill HC clinical testing, and whether the stated second-half 2024 target is achieved.
- Further clinical data and development plans for RT-111 and other candidates.
- Debt repayment terms, covenant compliance, and whether the uncommitted loan tranche becomes available.
- Restructuring completion and expected cost savings, as well as the costs of the new lease and related-party facility arrangements.
- Developments in the Novo Nordisk patent oppositions and any change in the potential TRA obligation.